

1229.2

1634

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

Application Number

09/832,621

Filing Date

April 11, 2001

First Named Inventor

RAUCY, Judy

Art Unit

1634

Examiner Name

SHEINBERG, Monika

Attorney Docket Number

PUR-00114.P.1.1

ENCLOSURES (Check all that apply)



Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)



Response to Missing Parts/
Incomplete Application



Response to Missing Parts
under 37 CFR 1.52 or 1.53



Drawing(s)



Licensing-related Papers



Petition



Petition to Convert to a
Provisional Application



Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____



After Allowance Communication
to a Technology Center (TC)



Appeal Communication to Board
of Appeals and Interferences



Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)



Proprietary Information



Status Letter



Other Enclosure(s) (please
Identify below):

Remarks

1. Form 1449
2. 2 Volumes of references
3. Return Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm

or

Individual

Signature

David R. Preston
Reg. No. 38,740

Date

Sept 30, 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: Oct 1, 2003

Typed or printed

Raymond Wagerknecht

Signature


Raymond Wagerknecht

Date

Oct 1, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$ 180.00)

Complete if Known

Application Number	09/832,621
Filing Date	April 11, 2001
First Named Inventor	RAUCY, Judy
Examiner Name	SHEINBERG, Monika
Art Unit	1634
Attorney Docket No.	PUR-00114.P.1.1

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit Account Number
Deposit Account Name

501321

David R. Preston

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)			(\$ 0.00)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	-20** =	X	
Independent Claims	-3** =	X	
Multiple Dependent			

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$ 0.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180.00
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00)**SUBMITTED BY**

Name (Print/Type) David R. Preston

Registration No. (Attorney/Agent)

38,710

(Complete if applicable)

Telephone 858-724-0375

Signature

Date

Sep 20, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Patent

Docket Number: PUR-00114.P.1.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Raucy

Application No.: 09/832,621

Filed: April 11, 2001

For: COMPOSITIONS AND
METHODS FOR INDUCTION OF
PROTEINS INVOLVED IN
XENOBIOTIC METABOLISM

Examiner: Monika Sheinberg

Art Unit: 1634

Commissioner for Patents
Alexandria VA 22313

Sir:

INFORMATION DISCLOSURE STATEMENT #3

Applicant respectfully submits this Information Disclosure Statement (IDS) after the mailing of a First Office Action on the merits under 37 C.F.R. §1.97(a)(3).

Applicant also submits a Form 1449, volumes of references cited on Applicant's Form 1449, and a check for \$180.00 to cover the IDS fee.

10/03/2003 RECEIVED 000000 0 00000000

01 000000


000000 00

Information Disclosure Statement
PUR-00114.P.1.1
Raucy

Please apply any charges not covered, or any credits, to Deposit Account number 501321 in the name of David R. Preston & Associates, having Customer Number 24232.

Respectfully submitted,

Date: Sept 30, 2003


David R. Preston
Reg. No. 38,710

David R. Preston & Associates
12625 High Bluff Drive
Suite 205
San Diego, CA 92130
phone: 858.724.0375
facsimile: 858.724.0384



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Docket Number: PUR-00114.P.1.1	Application Number: 09/832,621
	Applicant: Raucy	
	Filing Date: April 11, 2001	Group Art Unit: 1634


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	P1	5,071,773	12/10/91	Evans et al.			
	P2	5,298,429	3/29/94	Evans et al.			
	P3	5,639,616	6/17/97	Liao et al.			
	P4	2002/022599	2/21/02	Synold et al.			
	P5	2002/0150915	10/17/02	Berkenstam et al.			
	P6	2002/0168623	11/14/02	Raucy			
	P7	2003/0064430	4/03/03	Evans et al.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	Translation	
							YES	NO
	F1	EP 0 644 267 A2	7/20/94	EPO				
	F2	WO 88/03168	5/5/88	PCT				
	F3	WO 94/27557	12/8/94	PCT				
	F4	WO 99/61622	12/2/99	PCT				
	F5	WO 01/20026 A2	3/22/01	PCT				
	F6	WO 01/71361 A1	9/27/01	PCT				
	F7	WO 01/97856 A2	12/27/01	PCT				
	F8	WO 02/24918 A1	3/28/02	PCT				
	F9	WO 02/36784 A1	5/10/02	PCT				
	F10	WO 02/088305 A2	11/7/02	PCT				
	F11	WO 02/094865 A1	11/28/02	PCT				
	F12	WO 02/095652 A1	11/28/02	PCT				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D1	Barwick, Mol. Pharmacol., 50:10-16 (1996).
	D2	Dogra et al., Clinical Pharmacology and Physiology, 25: 1-9 (1998).
	D3	Chen et al., Mol. Pharmacol., 64:316-324 (2003).
	D4	Cui et al., Journal of Pharmacology and Toxicological Methods, 47: 143-151 (2002).
	D5	Ferguson et al., Mol. Pharmacol. 62(3): 737-746 (2002).
	D6	Gonzalez et al., DNA, 7(2): 79-86 (1988).
	D7	Hakkola et al., Critical Reviews in Toxicology, 28(1): 35-72 (1998)
	D8	Hashimoto et al., Eur. J. Biochem., 218: 585-595 (1993).
	D9	Honkakoski et al., Ann. Med. 35(3): 172-182 (2003).
	D10	Kliwer et al., Cell, 92:73-82 (1998).
	D11	Kolars et al., Pharmacogenetics 4: 247-259 (1994).
	D12	Kovaleva et al., Biochemical and Biophysical. Research Communications 221: 129-132 (1996).
	D13	Moore et al., Molecular Endocrinology 16(5):977-986 (2002).
	D14	Ogg et al., Eur. J. of Drug Metabolism and Pharmacokinetics 22(4): 311-313 (1997).
	D15	Sakai and Takigami, Ind. Health 41: 205-214 (2003).
	D16	Smith et al., Xenobiotica, 28(12): 1129-1165 (1998).
	D17	Sonoda et al., Proc. Natl. Acad. Sci USA 99(21): 13801-13806 (2002).
	D18	Sulston and Waterston, Genome Res., 8(11): 1097-1108 (1998).
	D19	Xie et al., Proc Natl. Acad. Sci. USA 100(7): 4150-4155 (2003).
	D20	Yanagida et al., Molecular and Cellular Biology, 10(4): 1470-1475 (1990).
	D21	Yueh et al., J of Biological Chemistry 278(17): 15001-15006 (2003).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--